Vitamin D Status, Cardiovascular Risk Profile, and miRNA-21 Levels in Hypertensive Patients: Results of the HYPODD Study
The vitamin D and microRNA (miR) systems may play a role in the pathogenesis of cardiometabolic disorders, including hypertension. The HYPODD study was a double-blind placebo-controlled trial aiming to assess the effects of cholecalciferol treatment in patients with well-controlled hypertension and...
| Main Authors: | , , , , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
MDPI AG
2022-06-01
|
| Series: | Nutrients |
| Subjects: | |
| Online Access: | https://www.mdpi.com/2072-6643/14/13/2683 |
| _version_ | 1797408450016182272 |
|---|---|
| author | Domenico Rendina Lanfranco D′Elia Veronica Abate Andrea Rebellato Ilaria Buondonno Mariangela Succoio Fabio Martinelli Riccardo Muscariello Gianpaolo De Filippo Patrizia D′Amelio Francesco Fallo Pasquale Strazzullo Raffaella Faraonio |
| author_facet | Domenico Rendina Lanfranco D′Elia Veronica Abate Andrea Rebellato Ilaria Buondonno Mariangela Succoio Fabio Martinelli Riccardo Muscariello Gianpaolo De Filippo Patrizia D′Amelio Francesco Fallo Pasquale Strazzullo Raffaella Faraonio |
| author_sort | Domenico Rendina |
| collection | DOAJ |
| description | The vitamin D and microRNA (miR) systems may play a role in the pathogenesis of cardiometabolic disorders, including hypertension. The HYPODD study was a double-blind placebo-controlled trial aiming to assess the effects of cholecalciferol treatment in patients with well-controlled hypertension and hypovitaminosis D (25OHD levels < 50 nmol/L). In addition to this clinical trial, we also evaluated the effects of cholecalciferol and calcitriol treatment on miR-21 expression in vivo and in vitro, respectively. Changes in the cardiovascular risk profiles were evaluated in HYPODD patients treated with cholecalciferol (C-cohort) or with placebo (P-cohort). The miR-21circulating levels were measured in four C-cohort patients and five P-cohort patients. In vitro, the miR-21 levels were measured in HEK-293 cells treated with calcitriol or with ethanol vehicle control. Cholecalciferol treatment increased 25OHD levels and reduced parathormone, total cholesterol, and low-density lipoprotein cholesterol levels in C-cohort patients, whereas no significant changes in these parameters were observed in P-cohort patients. The miR-21 circulating levels did not change in the C- or the P-cohort patients upon treatment. Calcitriol treatment did not affect miR-21 levels in HEK-293 cells. In conclusion, hypovitaminosis D correction ameliorated the cardiovascular risk profiles in hypertensive patients treated with cholecalciferol but did not influence the miR-21 expression. |
| first_indexed | 2024-03-09T03:58:40Z |
| format | Article |
| id | doaj.art-9a6700d35ff64f8988021ea9c5eeb95e |
| institution | Directory Open Access Journal |
| issn | 2072-6643 |
| language | English |
| last_indexed | 2024-03-09T03:58:40Z |
| publishDate | 2022-06-01 |
| publisher | MDPI AG |
| record_format | Article |
| series | Nutrients |
| spelling | doaj.art-9a6700d35ff64f8988021ea9c5eeb95e2023-12-03T14:16:32ZengMDPI AGNutrients2072-66432022-06-011413268310.3390/nu14132683Vitamin D Status, Cardiovascular Risk Profile, and miRNA-21 Levels in Hypertensive Patients: Results of the HYPODD StudyDomenico Rendina0Lanfranco D′Elia1Veronica Abate2Andrea Rebellato3Ilaria Buondonno4Mariangela Succoio5Fabio Martinelli6Riccardo Muscariello7Gianpaolo De Filippo8Patrizia D′Amelio9Francesco Fallo10Pasquale Strazzullo11Raffaella Faraonio12Department of Clinical Medicine and Surgery, Federico II University, 80131 Naples, ItalyDepartment of Clinical Medicine and Surgery, Federico II University, 80131 Naples, ItalyDepartment of Clinical Medicine and Surgery, Federico II University, 80131 Naples, ItalyDepartment of Medicine, Clinica Medica 3, University of Padova, 35122 Padova, ItalyDepartment of Medical Science, Geriatric and Bone Diseases Unit, University of Turin, 10124 Torino, ItalyDepartment of Molecular Medicine and Medical Biotechnology, Federico II University, 80131 Naples, ItalyDepartment of Molecular Medicine and Medical Biotechnology, Federico II University, 80131 Naples, ItalyDepartment of Clinical Medicine and Surgery, Federico II University, 80131 Naples, ItalyAssistance Publique—Hôpitaux de Paris, Hôpital Robert Debré, Service d’Endocrinologie et Diabétologie Pédiatrique, 75015 Paris, FranceDepartment of Medical Science, Geriatric and Bone Diseases Unit, University of Turin, 10124 Torino, ItalyDepartment of Medicine, Clinica Medica 3, University of Padova, 35122 Padova, ItalyDepartment of Clinical Medicine and Surgery, Federico II University, 80131 Naples, ItalyDepartment of Molecular Medicine and Medical Biotechnology, Federico II University, 80131 Naples, ItalyThe vitamin D and microRNA (miR) systems may play a role in the pathogenesis of cardiometabolic disorders, including hypertension. The HYPODD study was a double-blind placebo-controlled trial aiming to assess the effects of cholecalciferol treatment in patients with well-controlled hypertension and hypovitaminosis D (25OHD levels < 50 nmol/L). In addition to this clinical trial, we also evaluated the effects of cholecalciferol and calcitriol treatment on miR-21 expression in vivo and in vitro, respectively. Changes in the cardiovascular risk profiles were evaluated in HYPODD patients treated with cholecalciferol (C-cohort) or with placebo (P-cohort). The miR-21circulating levels were measured in four C-cohort patients and five P-cohort patients. In vitro, the miR-21 levels were measured in HEK-293 cells treated with calcitriol or with ethanol vehicle control. Cholecalciferol treatment increased 25OHD levels and reduced parathormone, total cholesterol, and low-density lipoprotein cholesterol levels in C-cohort patients, whereas no significant changes in these parameters were observed in P-cohort patients. The miR-21 circulating levels did not change in the C- or the P-cohort patients upon treatment. Calcitriol treatment did not affect miR-21 levels in HEK-293 cells. In conclusion, hypovitaminosis D correction ameliorated the cardiovascular risk profiles in hypertensive patients treated with cholecalciferol but did not influence the miR-21 expression.https://www.mdpi.com/2072-6643/14/13/2683hypertensionmiR-21hypovitaminosis Dcholecalciferolcalcitriolclinical trial |
| spellingShingle | Domenico Rendina Lanfranco D′Elia Veronica Abate Andrea Rebellato Ilaria Buondonno Mariangela Succoio Fabio Martinelli Riccardo Muscariello Gianpaolo De Filippo Patrizia D′Amelio Francesco Fallo Pasquale Strazzullo Raffaella Faraonio Vitamin D Status, Cardiovascular Risk Profile, and miRNA-21 Levels in Hypertensive Patients: Results of the HYPODD Study Nutrients hypertension miR-21 hypovitaminosis D cholecalciferol calcitriol clinical trial |
| title | Vitamin D Status, Cardiovascular Risk Profile, and miRNA-21 Levels in Hypertensive Patients: Results of the HYPODD Study |
| title_full | Vitamin D Status, Cardiovascular Risk Profile, and miRNA-21 Levels in Hypertensive Patients: Results of the HYPODD Study |
| title_fullStr | Vitamin D Status, Cardiovascular Risk Profile, and miRNA-21 Levels in Hypertensive Patients: Results of the HYPODD Study |
| title_full_unstemmed | Vitamin D Status, Cardiovascular Risk Profile, and miRNA-21 Levels in Hypertensive Patients: Results of the HYPODD Study |
| title_short | Vitamin D Status, Cardiovascular Risk Profile, and miRNA-21 Levels in Hypertensive Patients: Results of the HYPODD Study |
| title_sort | vitamin d status cardiovascular risk profile and mirna 21 levels in hypertensive patients results of the hypodd study |
| topic | hypertension miR-21 hypovitaminosis D cholecalciferol calcitriol clinical trial |
| url | https://www.mdpi.com/2072-6643/14/13/2683 |
| work_keys_str_mv | AT domenicorendina vitamindstatuscardiovascularriskprofileandmirna21levelsinhypertensivepatientsresultsofthehypoddstudy AT lanfrancodelia vitamindstatuscardiovascularriskprofileandmirna21levelsinhypertensivepatientsresultsofthehypoddstudy AT veronicaabate vitamindstatuscardiovascularriskprofileandmirna21levelsinhypertensivepatientsresultsofthehypoddstudy AT andrearebellato vitamindstatuscardiovascularriskprofileandmirna21levelsinhypertensivepatientsresultsofthehypoddstudy AT ilariabuondonno vitamindstatuscardiovascularriskprofileandmirna21levelsinhypertensivepatientsresultsofthehypoddstudy AT mariangelasuccoio vitamindstatuscardiovascularriskprofileandmirna21levelsinhypertensivepatientsresultsofthehypoddstudy AT fabiomartinelli vitamindstatuscardiovascularriskprofileandmirna21levelsinhypertensivepatientsresultsofthehypoddstudy AT riccardomuscariello vitamindstatuscardiovascularriskprofileandmirna21levelsinhypertensivepatientsresultsofthehypoddstudy AT gianpaolodefilippo vitamindstatuscardiovascularriskprofileandmirna21levelsinhypertensivepatientsresultsofthehypoddstudy AT patriziadamelio vitamindstatuscardiovascularriskprofileandmirna21levelsinhypertensivepatientsresultsofthehypoddstudy AT francescofallo vitamindstatuscardiovascularriskprofileandmirna21levelsinhypertensivepatientsresultsofthehypoddstudy AT pasqualestrazzullo vitamindstatuscardiovascularriskprofileandmirna21levelsinhypertensivepatientsresultsofthehypoddstudy AT raffaellafaraonio vitamindstatuscardiovascularriskprofileandmirna21levelsinhypertensivepatientsresultsofthehypoddstudy |